{"id":"W2748908606","doi":"10.1200/jco.2015.33.15_suppl.tps5072","title":"A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Tolerability; Oncology; Internal medicine; Clinical endpoint; Androgen receptor; Abiraterone; Phases of clinical research; Abiraterone acetate; Pharmacokinetics; Pharmacology; Adverse effect; Cancer; Androgen deprivation therapy; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001711036,0.001958292,0.001604719,0.0005926925,0.0004219548,0.0009060256,0.001063848,0.001556531,0.004801003],"category_scores_gemma":[0.000972677,0.0007491711,0.001025139,0.0004085918,0.001162878,0.001297234,0.0003262649,0.003289463,0.001194407],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001096007,"about_ca_system_score_gemma":0.001855092,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001294163,"about_ca_topic_score_gemma":0.004415468,"domain_scores_codex":[0.9995425,0.0001918366,0.00001765916,0.00008545984,0.00005969256,0.0001029564],"domain_scores_gemma":[0.999162,0.000118442,0.0001759757,0.00007351621,0.00006303605,0.0004071228],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6002163,0.2048825,0.0045073,0.0008964496,0.0008872288,0.0003413272,0.0003611586,0.003133142,0.08869351,0.0004060885,0.005886357,0.08978862],"study_design_scores_gemma":[0.2827418,0.6992312,0.00808212,0.00002696815,0.0002857637,0.0003325141,0.00006154823,0.001237752,0.004975732,0.0002682567,0.002719888,0.00003649639],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9886622,0.001586214,0.001169204,0.0003249916,0.0001215094,0.003982489,0.001849063,0.0002121841,0.002092195],"genre_scores_gemma":[0.9786456,0.001751516,0.003781424,0.001263903,0.0001978757,0.005050975,0.004131243,0.00007476548,0.005102661],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004801003,"threshold_uncertainty_score":0.01606095,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2169676562515597,"score_gpt":0.5335928390271395,"score_spread":0.3166251827755798,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}